

## **Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma**

Louis Chesler,<sup>1,5,^</sup> David D. Goldenberg,<sup>2,^</sup> Isha T. Seales,<sup>2</sup> Ronit Satchi-Fainaro,<sup>7</sup> Matt Grimmer,<sup>1</sup> Rodney Collins,<sup>6</sup> Chris Struett,<sup>2</sup> Kim N. Nguyen,<sup>2</sup> Grace Kim,<sup>6</sup> Tarik Tihan,<sup>6</sup> Yun Bao,<sup>2</sup> Rolf A. Brekken,<sup>8</sup> Gabriele Bergers,<sup>3,4,5</sup> Judah Folkman,<sup>9</sup> and William A. Weiss<sup>1,2,3,4,5</sup>

Equal Contribution <sup>^</sup>

Departments of <sup>1</sup>Pediatrics,<sup>2</sup>Neurology, <sup>3</sup>Neurological Surgery, <sup>4</sup>Brain Tumor Research Center,<sup>5</sup>Comprehensive Cancer Center and <sup>6</sup>Pathology, University of California San Francisco Medical School, San Francisco, CA 94143, <sup>7</sup>Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, <sup>8</sup>Departments of Surgery and Pharmacology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, and <sup>9</sup>Departments of Surgery and Cellular Biology, Harvard Medical School and Children's Hospital, Boston, MA 02115.

Correspondence: William A. Weiss, MD-PhD, Dept. of Neurology, UCSF, 533 Parnassus Ave., Rm U441O, San Francisco CA 94143, weiss@cgl.ucsf.edu, p (415) 502-1694; f (415) 476-0133

Grant numbers and sources of support: National Institutes of Health (grants R01CA102321, P30HD28825, K08NS053530-01A3), the Campini Family Foundation, the Thrasher Research Fund and the Samuel Waxman Cancer Research Foundation.

Running title: Anti-angiogenic therapy of neuroblastoma

Key Words: *MYCN*, neuroblastoma, angiogenesis, TNP-470, caplostatin

## Supplemental Figure Legends

**Supplemental Figure 1.** RT-PCR detection of MMP-9 and L-19 in neuroblastoma tumors as a function of group. RT + = reverse transcriptase positive; RT - = reverse transcriptase negative. Sequences of the MMP-9 and L-19 primers used in the RT-PCR reactions are shown below the figure.

**Supplemental Figure 2.** Weight loss in animals treated with TNP-470. Average weight of animal cohorts treated in Fig. 4 was 28g +/- 3g in the DMSO treated controls, 21g +/- 2g (>15% of total body weight loss) in the TNP-470 cohort ( $p < 0.01$ ), and was not significantly different in the caplostatin treated cohort. Data represent mean +/- s.e. (n = 8 mice per group).

**Supplemental Figure 3.** Rotarod testing of caplostatin treated animals. To assess neurotoxicity in animals treated with caplostatin, rotarod testing was performed, prior to and after two weeks of therapy. No significant difference in performance was detected between caplostatin treated and saline treated controls ( $p < 0.05$ ). Data represent mean +/- s.e. (n = 8 mice per group).